CG Oncology, Inc. (CGON) vs Erasca, Inc. (ERAS)
- CG Oncology, Inc. CGON 59.79 −3.35%
- Erasca, Inc. ERAS 13.39 −9.95%
CG Oncology, Inc. and Erasca, Inc. are both Biotechnology companies. CG Oncology, Inc. and Erasca, Inc. are of similar size ($5.5B and $5.2B). Erasca, Inc. has the higher net margin (0.00% vs −3,602.7%) and the higher return on invested capital (−203.1% vs −4,111.6%). Across the 14 metrics below, Erasca, Inc. leads on 8 and CG Oncology, Inc. on 6.
Valuation
Profitability
| Metric | CGON | ERAS | Biotechnology median |
|---|---|---|---|
| Gross margin | (85.20%) | 0.00% | 65.16% |
| Operating margin | (4,056.18%) | 0.00% | 0.00% |
| Net margin | (3,602.68%) | 0.00% | 0.00% |
| Free cash flow margin | (2,879.62%) | 0.00% | 0.00% |
| Return on equity | (26.41%) | (78.25%) | (56.36%) |
| Return on assets | (25.11%) | (65.25%) | (48.04%) |
| Return on invested capital | (4,111.64%) | (203.13%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack